Processa Pharmaceuticals Announces Strategic Portfolio Review, Pipeline Realignment, and $7M Capital Infusion

Processa Pharmaceuticals, Inc.

Terminated licensing agreement with Ocuphire Pharma (now Opus Genetics) for PCS3117, returning rights to original licensor.
Signed binding term sheet with Intact Therapeutics granting exclusive option to license PCS12852; eligible for up to $454M milestones and 12% royalty.
Continues enrolling patients in Phase 2 study of PCS6422 (NGC-Cap) for metastatic breast cancer; interim data expected H2 2025.
Strengthened balance sheet with $7 million capital infusion.
Establishing dedicated subsidiary for PCS499; designing new adaptive pivotal Phase III study for rare kidney disease.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.